Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27581168 | 0.81 | SLC6A3 (0.39) | SLC6A3CYP2D6CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL20745345 | 0.81 | SLC6A3 (0.39) | SLC6A3CYP2D6CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL5250314 | 0.81 | PGK1 (0.42) | CYP3A4IDO1PGK1PGK2CES2 | |
| SCHEMBL4083168 | 0.79 | IDO1 (0.37) | SLC6A3CYP2D6CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL5704333 | 0.78 | CYP3A4 (0.34) | SLC6A3CYP2D6CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL18243393 | 0.76 | SLC6A3 (0.36) | SLC6A3CYP2D6CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL4062829 | 0.76 | SLC6A3 (0.33) | SLC6A3CYP2D6CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL6345064 | 0.75 | CYP3A4 (0.47) | SLC6A3CYP2D6CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL9016042 | 0.75 | CYP2D6 (0.41) | SLC6A3CYP2D6CYP3A4SLC6A2SLC6A4 | |
| SCHEMBL2491629 | 0.75 | CYP2D6 (0.41) | SLC6A3CYP2D6CYP3A4SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615573-A1 | GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | Eli Lilly and Company (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4540230-A1 | ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | Ensem Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2024102625-A1 | GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2023244710-A1 | ANILINO-PYRAZOLE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-2655378-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | AstraZeneca AB (SE) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012087237-A1 | COMPOUNDS AND THEIR USE AS BACE INHIBITORS | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | disclosed |
| EP-2406240-A2 | INHIBITORS OF BETA-SECRETASE | Vitae Pharmaceuticals, Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| WO-2011127383-A2 | BORON-CONTAINING PI-ELECTRON MATERIALS INCORPORATING FORMALLY AROMATIC AND NEUTRAL BOREPIN RINGS | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2010105179-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| EP-1389194-A2 | INHIBITORS OF BACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20030095958-A1 | Inhibitors of bace | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-22 | — | — | US | disclosed |
| WO-2002088101-A2 | INHIBITORS OF BACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030095958-A1 | Inhibitors of bace | BACE2, BACE1, APP | SLC6A3 1280/4885CYP2D6 3935/4885CYP3A4 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.